The risk for developing Guillain-Barré syndrome, a condition that causes severe muscle weakness, after receipt of a COVID-19 vaccine is small, but higher with the
Of recipients of more than 480,000 doses of the one-shot
Among recipients of one of the two-shot mRNA vaccines from
The findings suggest that the risk for the complication may be 20% higher with the
"[We] found a small, increased risk of Guillain-Barré syndrome, a rare neurological disorder, during the three weeks after [
"Individuals who choose to receive [
The
Guillain-Barré syndrome causes rapid-onset muscle weakness as a result of the immune system attacking the peripheral nervous system in error, according to the
It has been associated with COVID-19, specifically "long COVID," or persistent viral symptoms, in previous studies, and has also been reported among recipients of the vaccines against the virus, particularly the
For this study, Klein and her colleagues analyzed side effect data for more than 8.8 million doses of the Pfizer-BioNTech vaccine, more than 5.8 million doses of the
They focused specifically on reports of Guillain-Barré syndrome, which can be disabling, they said.
Within three weeks of vaccine administration, there were six cases of Guillain-Barré syndrome reported for every 100,000 recipients of the
For the
"This study did not identify any specific group at increased risk for Guillain-Barré syndrome from the J&J vaccine," Klein said.
Copyright 2022 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source